Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ACP-104
DRUG: ACP-104
DRUG: Placebo

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]